Speaker Profile

General Manager, Precision Oncology, Exact Sciences

Matt Franklin is the General Manager of Precision Oncology for Exact Sciences. Prior to joining Exact Sciences, Matt served as the Chief Commercial Officer for Thrive Earlier Detection, where was responsible for defining the go-to-market strategy for their multi-cancer early detection assay, CancerSEEK. Prior to his role with Thrive, Matt was the Chief Business Officer for ArcherDX, a growth-stage molecular diagnostics company, and also served as the Senior Vice President of Global Marketing and Clinical Product Strategy at Foundation Medicine where he led the global launch of the company’s first liquid biopsy offering and the first FDA-approved, CMS-covered, comprehensive genomic profiling companion diagnostic test.

 Session Abstract – PMWC 2022 Silicon Valley

Alzheimer’s disease is one of our nation’s most significant threats, with devastating impacts on patients and their families. This session will explore a new approach called neurodiagnostic therapies, a methodology fundamentally enabled by ultrasensitive biomarker measurements that allow visibility to neurological disease in individuals before they are symptomatic. This allows treatment to be administered at a more optimal stage, to improve therapeutic effectiveness and by extension, patient outcomes.

During this presentation, attendees will learn how this new approach can provide early treatment to ultimately accelerate disease detection and improve outcomes, in addition to creating viable and credible evidence for the healthcare system to adopt it with coverage to facilitate frictionless access.